3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success
Extending its winning streak, GW Pharmaceuticals says the second Phase III for Epidiolex in treating Lennox-Gastaut syndrome — a rare form of epilepsy — has also come through with solidly positive efficacy data. And the UK biotech is now planning to hustle ahead with a new drug application at the FDA in the coming months.
The data from this second study on the company’s lead cannabinoid therapy were even better than the first, with a median 42% drop in monthly seizures, compared to 17% in the placebo group for a 20 mg dose. The 10 mg dose was also a success, with a 37% drop in the seizure rate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.